Skip to content

Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access

Role of Regular Surveillance on Maintenance of Patency of an Arteriovenous Access

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04098159
Enrollment
200
Registered
2019-09-23
Start date
2019-11-01
Completion date
2021-07-01
Last updated
2019-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Access Failure

Brief summary

Chronic Kidney disease (CKD) is a worldwide public health problem that classified into five stages (1). End stage renal disease (CDK stage 5) patients require a well-functioning vascular access (VA) for successful hemodialysis treatment (2). Types of VA include arteriovenous fistulae (AVFs) and arteriovenous grafts (AVGs). A vascular access is liable to early or late complications, and ultimately access failure. A meta-analysis showed that a 17% mean early access failure However recent studies have shown higher failure rates of up to 46%, with one year patencies between 52% to 83% (3). Low VA flow, thrombosis and loss of patency may result in under-dialysis that leads to increased morbidity, mortality and healthcare expenditure (4). In the majority of VAs, stenoses develop over variable intervals causing VA thrombosis and failure (5). If early detected and corrected, VA function and patency can be preserved and under-dialysis can be minimized or avoided. The aim of this study is to find out the role of periodic surveillance of VA in the detection of VA dysfunction and correctable lesions that may necessitate pre-emptive interventions to maintain VA patency and prevent VA loss

Interventions

regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* ESRD Patients have functioning or failing VAs (AVFs or AVGs).

Exclusion criteria

* ESRD patients have infected or failed VAs . * patientrefusal .

Design outcomes

Primary

MeasureTime frame
Number, type and technical success rate for elective interventionswithin one year of creation of the VA

Secondary

MeasureTime frame
secondary patency rate of the Arteriovenous Access after elective interventionwithin one year of creation of the VA
number , type of complication that resulted from elective interventionswithin one year of creation of the VA
primary patency rate of newly created Arteriovenous Access in assiut governoratewithin one year of creation of the VA

Contacts

Primary Contactahmed m rashed, resident
ahmedrashed9933@gmail.com00201064252719

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026